Breast Cancer Coverage from Every Angle

Hope S. Rugo, MD, on KEYNOTE-355 Findings on Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Posted: Monday, November 22, 2021

Hope S. Rugo, MD, of the University of California, San Francisco, discusses the clinical implications of phase III results that support the use of pembrolizumab plus chemotherapy to treat women with triple-negative breast cancer, the adverse effects that could occur, and the ideal candidate for this regimen.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.